Amicogen, Inc. (KOSDAQ: 092040)

Market Cap	197.61B
Revenue (ttm)	155.74B
Net Income (ttm)	-35.70B
Shares Out	54.82M
EPS (ttm)	-693.74
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	220,934
Open	n/a
Previous Close	n/a
Day's Range	n/a
52-Week Range	3,075.00 - 9,400.00
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Jan 31, 2025

About Amicogen

Amicogen, Inc. operates as an industrial biotechnology company in South Korea and internationally. The company offers bio-ingredients, such as N-acetylglucosamine for skin moisturizing and joint health; pinitol/D-chiro-inositol; collagen peptide and collagen tripeptide for skin and health; chitoslim and chitosan oligosaccharides, as well as fucoxanthin, curezyme, food enzyme, and bamboo salt. It also offers specialty enzymes, including CX, SP, etc. for pharmaceutical, food, and feed sectors. In addition, the company offers K-nutra, a healthcare...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2000
• Employees: 225
• Stock Exchange: KOSDAQ
• Ticker Symbol: 092040

Financial Performance

In 2023, Amicogen's revenue was 159.90 billion, an increase of 10.82% compared to the previous year's 144.30 billion. Losses were -23.29 billion, -50.68% less than in 2022.